Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer
Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer
复制标题
患者来源的类器官预测局部晚期直肠癌的放化疗反应
DOI：
10.1016/j.stem.2019.10.010
复制
发表时间：
2020-01-01
期刊：
影响因子：
23.9
通讯作者：
Hua, Guoqiang
中科院分区：
文献类型：
--
作者：
Yao, Ye;Xu, Xiaoya;Hua, Guoqiang
越来越多的证据表明，患者源性类器官（PDOs）可以在临床中预测药物反应，但PDOs预测癌症患者对放化疗反应的能力仍然是一个悬而未决的问题。在这里，我们从接受新辅助放化疗（NACR）的局部晚期直肠癌（LARC）患者中生成一个活体类器官生物库，这些患者参加了一项III期临床试验。我们的联合临床试验数据证实，直肠癌类器官（RCOs）密切概括了相应肿瘤的病理生理和遗传变化。患者的放化疗反应与RCO反应高度匹配，准确率为84.43%，敏感性为78.01%，特异性为91.97%。这些数据表明，PDOs可以预测LARC患者的临床反应，并可能代表直肠癌治疗的伴随诊断工具。
Accumulating evidence indicates that patient-derived organoids (PDOs) can predict drug responses in the clinic, but the ability of PDOs to predict responses to chemoradiation in cancer patients remains an open question. Here we generate a living organoid biobank from patients with locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiation (NACR) enrolled in a phase III clinical trial. Our co-clinical trial data confirm that rectal cancer organoids (RCOs) closely recapitulate the pathophysiology and genetic changes of corresponding tumors. Chemoradiation responses in patients are highly matched to RCO responses, with 84.43% accuracy, 78.01% sensitivity, and 91.97% specificity. These data imply that PDOs predict LARC patient responses in the clinic and may represent a companion diagnostic tool in rectal cancer treatment.